SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-18-046811
Filing Date
2018-07-25
Accepted
2018-07-25 06:12:31
Documents
7
Period of Report
2018-07-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a18-17513_18k.htm 8-K 171747
2 EX-2.1 a18-17513_1ex2d1.htm EX-2.1 841723
3 EX-10.1 a18-17513_1ex10d1.htm EX-10.1 110312
4 EX-10.2 a18-17513_1ex10d2.htm EX-10.2 144581
5 EX-23.1 a18-17513_1ex23d1.htm EX-23.1 5481
6 EX-99.1 a18-17513_1ex99d1.htm EX-99.1 402172
7 EX-99.2 a18-17513_1ex99d2.htm EX-99.2 539557
  Complete submission text file 0001104659-18-046811.txt   2217249
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37558 | Film No.: 18967566
SIC: 2834 Pharmaceutical Preparations